AVEO Pharmaceuticals to Present at the Lazard Capital Markets Fifth Annual Healthcare Conference

Press Release

View printer-friendly version

<<  Back

AVEO Pharmaceuticals to Present at the Lazard Capital Markets Fifth Annual Healthcare Conference

CAMBRIDGE, Mass., November 12, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Lazard Capital Markets Fifth Annual Healthcare Conference on Wednesday, November 19, 2008 at 11:30 a.m. (ET) at the St. Regis in New York City.

About AVEO

AVEO is a late-stage biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO’s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals and Schering-Plough. The company’s lead product, AV-951, a potential best-in-class triple VEGF receptor inhibitor, is completing a Phase 2 clinical trial in more than 200 patients with metastatic renal cell cancer and is expected to enter Phase 3 development in 2009. Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a diversified product pipeline and moving toward its vision of becoming a fully integrated biopharmaceutical company. For more information, please visit the company's website at http://www.aveopharma.com/.